OCS-01’s positive results in Stage 1 of the Phase 3 DIAMOND trial for diabetic macular edema (DME) were presented as a late-breaking abstract showing that the trial met primary and secondary endpoints with robust statistical significanceOn track to commence Stage 2 of the DIAMOND program with two parallel global Phase 3 trialsIf approved, OCS-01 has the potential to become the first topical eye drop for the treatment of DME ZUG, Switzerland and BOSTON, Oct. 10, 2023 (GLOBE NEWSWIRE) Oculis Ho
ZUG, Switzerland, and BOSTON, Aug. 30, 2023 (GLOBE NEWSWIRE) Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced that Riad Sherif, MD, Chief Executive Officer, and Sylvia Cheung, Chief Financial Officer will be attending and presenting at the following upcoming investor conferences: H.C. Wainwright 25th Annual Global Investment Conference Format: Company presentation Presentation date and time: